Sorrento TherapeuticsがTRIBECA治験の有望な薬物動態データを発表

AsiaNet 60374（0586）

【サンディエゴ（米カリフォルニア州）2015年5月4日PRN＝共同通信JBN】Sorrento Therapeutics, Inc.（NASDAQ: SRNE）は4日、TRIBECA（TM）（Cynviloq(TM)とアルブミン結合パクリタキセルとの間の生物学的同等性確立のための臨床試験）治験から得られた薬物動態（PK）データを最近分析した肯定的結果を発表した。データ分析結果によると、Cynviloqは結合および非結合タクリパキセル双方の生物学的同等性（BE）基準に合うことが示された。安全評価が治験患者に対して現在行われているが突発的な有害事象は明らかになっておらず、安全性データはアルブミン結合パクリタキセルについて文字通り公表されている毒性プロファイルと一致している。

　Logo - http://photos.prnewswire.com/prnh/20150105/167173LOGO

▽Sorrento Therapeutics, Inc.について

Sorrentoはがんとそれに伴う痛みの新たな治療法を開発している腫瘍薬会社である。Sorrentoの最も進展しているアセットは、次世代ナノ粒子パクリタキセルであるCynviloq（TM）である。Sorrentoはまた難治性の痛みに苦しむ終末期のがん患者治療のために、米国立衛生研究所（NIH）で進行中の第1/2相試験で非麻薬系のTRPV1アゴニストであるレシニフェラトキシン（RTX）も開発中である。

Sorrento およびNantWorksは2014年12月、がんの免疫療法に注力するため、現在はNantibodyと呼称する世界的な合弁事業を結成した。また、Sorrentoおよび株式非公開のがん免疫療法企業でありNatural Killer（NK）細胞株療法の特許薬品Neukoplast（R）を開発しているConkwest, Inc.は同年12月、がんと感染症治療用のCAR.TNK（TM）（キメラ抗原受容体）免疫療法を共同開発する契約を結んだ。Sorrentoは2015年3月、腫瘍ネオエピトープ（tumor neo-epitopes）に対する免疫療法を発見、開発するため、NantWorksの傘下企業であるNantCellとの世界的コラボレーションに入った。

Sorrento（TM）、CAR.TNK（TM）TRIBECA（TM）、Sorrento logoおよびCynviloq（TM）はSorrento Therapeutics, Inc.が所有する商標である。

ソース：Sorrento Therapeutics, Inc.

▽問い合わせ先

Mr. George Uy,

EVP & Chief Commercial Officer, Sorrento Therapeutics, Inc.,

guy@sorrentotherapeutics.com,

T: + 1 (661) 607-4057

AsiaNet 60374 (0586)

Sorrento Announces Positive TRIBECA(TM) Registrational Study Results

PR60374

SAN DIEGO, May 4, 2015 /PRN=KYODO JBN/ --

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is pleased to announce positive

results from recently analyzed pharmacokinetic (PK) data from its TRIBECA

(TRIal establishing BioEquivalence between Cynviloq(TM) and Albumin-bound

paclitaxel) registrational trial. Data analysis suggests that Cynviloq meets

the bioequivalence (BE) criteria for both total and unbound paclitaxel. The

ongoing safety assessment from treated patients continues to reveal no

unexpected adverse events and the safety data is consistent with the toxicity

profile reported in the literature with albumin-bound paclitaxel.

Logo - http://photos.prnewswire.com/prnh/20150105/167173LOGO

About Sorrento Therapeutics, Inc.

Sorrento is an oncology company developing new treatments for cancer and

associated pain. Sorrento's most advanced asset is Cynviloq(TM), the

next-generation nanoparticle paclitaxel. Sorrento is also developing

resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2

study at the NIH to treat terminal cancer patients suffering from intractable

pain.

In December 2014, Sorrento and NantWorks formed a global joint venture, now

called Nantibody, to focus on immunotherapies for cancer. Also in December

2014, Sorrento and Conkwest, Inc., a privately-held immuno-oncology company

developing proprietary Neukoplast(R), a Natural Killer (NK) cell-line based

therapy, entered into an agreement to jointly develop CAR.TNK(TM) (Chimeric

Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment

of cancer and infectious diseases. In March 2015, Sorrento entered into a

global collaboration with NantCell, a NantWorks company, to discover and

develop immunotherapies against tumor neo-epitopes.

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento

Therapeutics, Inc. under the safe harbor provisions of Section 21E of the

Private Securities Litigation Reform Act of 1995 and subject to risks and

uncertainties that could cause actual results to differ materially from those

projected. Forward-looking statements include statements about the Cynviloq

registrational trial; Sorrento's advances made in developing RTX and CAR.TNKs,

if any; and other matters that are described in Sorrento's Annual Report on

Form 10-K for the year ended December 31, 2014, and subsequent Quarterly

Reports on Form 10-Q filed with the Securities and Exchange Commission,

including the risk factors set forth in those filings. Investors are cautioned

not to place undue reliance on these forward-looking statements, which speak

only as of the date of this release and we undertake no obligation to update

any forward-looking statement in this press release except as required by law.

Sorrento(TM), CAR.TNK(TM), TRIBECA(TM), the Sorrento logo and Cynviloq(TM) are

trademarks owned by Sorrento Therapeutics, Inc.

SOURCE: Sorrento Therapeutics, Inc.

CONTACT: Mr. George Uy, EVP & Chief Commercial Officer, Sorrento Therapeutics,

Inc., guy@sorrentotherapeutics.com, T: + 1 (661) 607-4057